Log in

NYSEARCA:PJPInvesco Dynamic Pharmaceuticals ETF Stock Price, Forecast & News

$63.68
+0.13 (+0.20 %)
(As of 05/26/2020 04:00 PM ET)
Add
Today's Range
$63.34
Now: $63.68
$63.69
50-Day Range
$54.37
MA: $61.57
$64.40
52-Week Range
$47.14
Now: $63.68
$66.75
Volume9,700 shs
Average Volume38,542 shs
Market Capitalization$359.79 million
P/E RatioN/A
Dividend Yield0.90%
BetaN/A
PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The Fund normally invests at least 90% of its total assets in common stocks that consists of the Index. The Fund's investment advisor is Invesco PowerShares Capital Management LLC.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.77 out of 5 stars


Basic Details

Issuer Invesco
Fund NameInvesco Dynamic Pharmaceuticals ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:PJP
Inception Date6/23/2005
Fund ManagerPeter Hubbard, Michael Jeanette, Tony Seisser, Jonathan Nixon
Phone+1-800-9830903

Fund Focus

Asset ClassEquity
BenchmarkDynamic Pharmaceuticals Intellidex Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$360.20 million
Average Daily Volume$35,352.70
Discount/Premium-0.03%

ETF Expenses

Management Fee0.50%
Other Expenses0.06%
Total Expenses0.56%
Fee Waiver0.00%
Net Expenses0.56%

Administrator, Advisor and Custodian

AdministratorThe Bank of New York Mellon Corporation
AdvisorInvesco Capital Management LLC
CustodianThe Bank of New York Mellon Corporation
DistributorInvesco Distributors, Inc.
Transfer AgentThe Bank of New York Mellon Corporation
Trustee
Lead Market MakerIMC Chicago

Receive PJP News and Ratings via Email

Sign-up to receive the latest news and ratings for PJP and its competitors with MarketBeat's FREE daily newsletter.

Geographic Exposure of Invesco Dynamic Pharmaceuticals ETF (NYSEARCA:PJP)
Currency Exposure of Invesco Dynamic Pharmaceuticals ETF (NYSEARCA:PJP)
Sector Exposure of Invesco Dynamic Pharmaceuticals ETF (NYSEARCA:PJP)
Industry Exposure of Invesco Dynamic Pharmaceuticals ETF (NYSEARCA:PJP)

Invesco Dynamic Pharmaceuticals ETF (NYSEARCA:PJP) Frequently Asked Questions

How has Invesco Dynamic Pharmaceuticals ETF's stock been impacted by COVID-19 (Coronavirus)?

Invesco Dynamic Pharmaceuticals ETF's stock was trading at $55.29 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PJP shares have increased by 15.2% and is now trading at $63.68. View which stocks have been most impacted by Coronavirus.

How often does Invesco Dynamic Pharmaceuticals ETF pay dividends? What is the dividend yield for Invesco Dynamic Pharmaceuticals ETF?

Invesco Dynamic Pharmaceuticals ETF declared a quarterly dividend on Monday, December 23rd. Investors of record on Tuesday, December 24th will be paid a dividend of $0.1619 per share on Tuesday, December 31st. This represents a $0.65 dividend on an annualized basis and a yield of 1.02%. The ex-dividend date is Monday, December 23rd. This is a boost from Invesco Dynamic Pharmaceuticals ETF's previous quarterly dividend of $0.06. View Invesco Dynamic Pharmaceuticals ETF's dividend history.

Has Invesco Dynamic Pharmaceuticals ETF been receiving favorable news coverage?

Media headlines about PJP stock have been trending extremely negative on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Invesco Dynamic Pharmaceuticals ETF earned a news impact score of -4.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutInvesco Dynamic Pharmaceuticals ETF.

What other stocks do shareholders of Invesco Dynamic Pharmaceuticals ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invesco Dynamic Pharmaceuticals ETF investors own include Verizon Communications (VZ), iShares Russell 2000 ETF (IWM), iShares 20+ Year Treasury Bond ETF (TLT), Akcea Therapeutics (AKCA), Morgan Stanley (MS), Applied Materials (AMAT), Alibaba Group (BABA), BOX (BOX), Berkshire Hathaway (BRK.B) and Walt Disney (DIS).

Who are Invesco Dynamic Pharmaceuticals ETF's key executives?

Invesco Dynamic Pharmaceuticals ETF's management team includes the following people:
  • H. Bruce Bond, Chairman of the Board of Trustee, Chief Executive Officer (Age 49)
  • Bruce T. Duncan, Chief Financial Officer, Treasurer (Age 60)
  • Kevin R. Gustafson, Chief Compliance Officer (Age 43)
  • Keith A Ovitt, Secretary (Age 50)
  • Ronn R. Bagge, Trustee (Age 55)
  • Marc M Kole, Trustee (Age 53)
  • D. Mark McMillan, Trustee (Age 49)
  • Philip M. Nussbaum Mba, Trustee (Age 52)
  • Donald H. Wilson, Trustee (Age 55)

What is Invesco Dynamic Pharmaceuticals ETF's stock symbol?

Invesco Dynamic Pharmaceuticals ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "PJP."

Who are Invesco Dynamic Pharmaceuticals ETF's major shareholders?

Invesco Dynamic Pharmaceuticals ETF's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (3.00%), Advisor Group Holdings Inc. (1.03%), Morgan Stanley (0.87%), Morgan Stanley (0.88%), UBS Group AG (0.65%) and Raymond James & Associates (0.53%).

Which institutional investors are selling Invesco Dynamic Pharmaceuticals ETF stock?

PJP stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Wells Fargo & Company MN, Envestnet Asset Management Inc., Commonwealth Equity Services LLC, Jane Street Group LLC, Patriot Financial Group Insurance Agency LLC, BTR Capital Management Inc., and Raymond James & Associates.

Which institutional investors are buying Invesco Dynamic Pharmaceuticals ETF stock?

PJP stock was purchased by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., Q3 Asset Management, 55I LLC, Cambridge Investment Research Advisors Inc., Morgan Stanley, Morgan Stanley, JPMorgan Chase & Co., and Bartlett & Co. LLC.

How do I buy shares of Invesco Dynamic Pharmaceuticals ETF?

Shares of PJP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Invesco Dynamic Pharmaceuticals ETF's stock price today?

One share of PJP stock can currently be purchased for approximately $63.68.

How big of a company is Invesco Dynamic Pharmaceuticals ETF?

Invesco Dynamic Pharmaceuticals ETF has a market capitalization of $359.79 million.

What is Invesco Dynamic Pharmaceuticals ETF's official website?

The official website for Invesco Dynamic Pharmaceuticals ETF is www.invescopowershares.com.

How can I contact Invesco Dynamic Pharmaceuticals ETF?

Invesco Dynamic Pharmaceuticals ETF's mailing address is 301 W. Roosevelt Road, Wheaton, 60187, United States. The company can be reached via phone at +1-800-9830903.

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.